Sanofi plans to apply for listing of isatuximab by the end of this year
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
In the icaria-mm study, 307 patients with relapsed and refractory multiple myeloma who had previously received more than two therapies including lenalidomide and / or a proteasome inhibitor were randomly divided into two groups and given standard treatment (pomalidomide + low dose dexamethasone) or standard treatment + isatuximab< br / > the results showed that the PFS was prolonged by 5 months (11.53 vs 6.47 months) and the risk of disease progression and death was reduced by 40% and the orr was also significantly increased (60% vs 35%) compared with the control groupIn addition, the time to receive the next treatment was significantly longer (immature vs9.1 months)< br / > in terms of safety, 86.8% and 70.5% of the patients in isatuximab + pomadolamine + dexamethasone group and pomadolamine + dexamethasone group had more than 3-level adverse events, 7.2% and 12.8% of the patients stopped treatment due to adverse events, and 7.9% and 9.4% of the patients died due to adverse events, respectivelyThe incidence of infection above level 3 was 42.8% and 30.2% respectivelyThe number of neutrophils above grade 3 was 84.9% and 70.1%, respectively< br / > darzalex (daratumumab) is the only monoclonal antibody of CD38 currently on the marketIt was approved in November 2015, and its global sales reached US $2.025 billion in 2018< br / > original title: isatuximab reduces the risk of progression or death by 40% in the treatment of relapsed refractory multiple myeloma
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.